Richard Law CFA
Stock Analyst at Goldman Sachs
(2.97)
# 2,552
Out of 4,339 analysts
122
Total ratings
39.3%
Success rate
4.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COAG Hemab Therapeutics Holdings | Maintained: Buy | $36 | $27.84 | +29.31% | 1 | May 26, 2026 | |
| MLYS Mineralys Therapeutics | Maintained: Buy | $42 | $29.99 | +40.05% | 11 | May 18, 2026 | |
| OLMA Olema Pharmaceuticals | Maintained: Buy | $27 → $23 | $13.55 | +69.74% | 9 | May 12, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintained: Sell | $11 → $12 | $18.23 | -34.17% | 8 | May 11, 2026 | |
| BCAX Bicara Therapeutics | Rated: Hold | $16 → $18 | $21.98 | -18.11% | 3 | May 11, 2026 | |
| CLDX Celldex Therapeutics | Maintained: Hold | $34 → $38 | $30.85 | +23.18% | 5 | May 8, 2026 | |
| RCUS Arcus Biosciences | Maintained: Buy | $30 → $34 | $24.13 | +40.90% | 3 | May 7, 2026 | |
| PTGX Protagonist Therapeutics | Maintained: Hold | $95 → $110 | $99.98 | +10.02% | 5 | May 6, 2026 | |
| VRDN Viridian Therapeutics | Rated: Buy | $36 → $31 | $17.00 | +82.35% | 8 | Apr 7, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintained: Sell | $3 | $3.00 | - | 7 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $4 | $6.64 | -39.76% | 3 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $67 | $36.78 | +82.16% | 5 | Mar 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $29 → $33 | $21.11 | +56.32% | 3 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $120 → $135 | $104.95 | +28.63% | 5 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $30 → $33 | $30.80 | +7.14% | 2 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $36 → $31 | $7.09 | n/a | 6 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $47 | $29.79 | n/a | 4 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $62 → $63 | $51.59 | n/a | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $36 → $37 | $80.74 | n/a | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $76 | $12.61 | n/a | 7 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 | $19.20 | n/a | 3 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $15 → $14 | $3.08 | n/a | 3 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $61 | $8.92 | n/a | 5 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $10 | $3.49 | n/a | 2 | Feb 24, 2023 |
Hemab Therapeutics Holdings
May 26, 2026
Maintained: Buy
Price Target: $36
Current: $27.84
Upside: +29.31%
Mineralys Therapeutics
May 18, 2026
Maintained: Buy
Price Target: $42
Current: $29.99
Upside: +40.05%
Olema Pharmaceuticals
May 12, 2026
Maintained: Buy
Price Target: $27 → $23
Current: $13.55
Upside: +69.74%
MoonLake Immunotherapeutics
May 11, 2026
Maintained: Sell
Price Target: $11 → $12
Current: $18.23
Upside: -34.17%
Bicara Therapeutics
May 11, 2026
Rated: Hold
Price Target: $16 → $18
Current: $21.98
Upside: -18.11%
Celldex Therapeutics
May 8, 2026
Maintained: Hold
Price Target: $34 → $38
Current: $30.85
Upside: +23.18%
Arcus Biosciences
May 7, 2026
Maintained: Buy
Price Target: $30 → $34
Current: $24.13
Upside: +40.90%
Protagonist Therapeutics
May 6, 2026
Maintained: Hold
Price Target: $95 → $110
Current: $99.98
Upside: +10.02%
Viridian Therapeutics
Apr 7, 2026
Rated: Buy
Price Target: $36 → $31
Current: $17.00
Upside: +82.35%
Rocket Pharmaceuticals
Mar 27, 2026
Maintained: Sell
Price Target: $3
Current: $3.00
Upside: -
Mar 5, 2026
Maintained: Sell
Price Target: $4
Current: $6.64
Upside: -39.76%
Mar 1, 2026
Maintained: Buy
Price Target: $67
Current: $36.78
Upside: +82.16%
Feb 27, 2026
Maintained: Hold
Price Target: $29 → $33
Current: $21.11
Upside: +56.32%
Nov 18, 2025
Maintained: Buy
Price Target: $120 → $135
Current: $104.95
Upside: +28.63%
Jul 24, 2025
Maintained: Hold
Price Target: $30 → $33
Current: $30.80
Upside: +7.14%
Aug 15, 2023
Maintained: Hold
Price Target: $36 → $31
Current: $7.09
Upside: n/a
Aug 9, 2023
Maintained: Hold
Price Target: $47
Current: $29.79
Upside: n/a
Aug 8, 2023
Maintained: Hold
Price Target: $62 → $63
Current: $51.59
Upside: n/a
Aug 4, 2023
Maintained: Hold
Price Target: $36 → $37
Current: $80.74
Upside: n/a
Jun 13, 2023
Reiterated: Buy
Price Target: $76
Current: $12.61
Upside: n/a
May 12, 2023
Reiterated: Hold
Price Target: $11
Current: $19.20
Upside: n/a
May 5, 2023
Maintained: Hold
Price Target: $15 → $14
Current: $3.08
Upside: n/a
May 5, 2023
Maintained: Buy
Price Target: $61
Current: $8.92
Upside: n/a
Feb 24, 2023
Upgraded: Hold
Price Target: $10
Current: $3.49
Upside: n/a